About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals is a publicly listed company based in Conshohocken (United States) founded in 2011, and was acquired by Synta Pharmaceuticals in April 2016. It develops small molecule drugs for the treatment of cardiovascular and metabolic diseases and non-alcoholic steatohepatitis. Madrigal Pharmaceuticals has raised $38.38 million across 2 funding rounds from investors including Madrigal. The company has 528 employees. Its website madrigalpharma.com draws about 54 thousand monthly visits. Madrigal Pharmaceuticals offers products and services including Rezdiffra. Its focus areas include Life Sciences, Metabolic Diseases, Drugs and Hepatic disorders. Its competitors include NGM Biopharmaceuticals, Nimbus Therapeutics and Altimmune; 3 of its 3 listed competitors have raised funding.
Company details
Madrigal Pharmaceuticals was founded in 2011 and is headquartered in Conshohocken, United States. Operations are centered on the development of small molecule therapeutics targeting cardiovascular and metabolic diseases, including non-alcoholic steatohepatitis. The company focuses on advancing drug candidates through clinical stages within the biopharmaceutical sector, with activities spanning research, preclinical testing, and regulatory processes in the United States.
- Headquarters Conshohocken, United States
- Employees 528
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Emailβ’β’β’β’β’β’β’β’
- Website madrigalpharma.com
- Social LinkedIn X
- Acquired by Synta Pharmaceuticals (Apr 2016)
- Legal Name Madrigal Pharmaceuticals, Inc.
- Annual Revenue$958.4 M (USD)432.05as on Dec 31, 2025
- Net Profit-$288.28 M (USD)38.12as on Dec 31, 2025
- EBITDA-$298.59 M (USD)39.89as on Dec 31, 2025
- Total Equity Funding$38.38M (USD)
in 2 rounds
- Latest Funding Round$35M (USD), Series A
Jun 2017
- Investors
- Employee Count528
- Acquired bySynta Pharmaceuticals
(Apr 2016)
Products & Services of Madrigal Pharmaceuticals
Madrigal Pharmaceuticals offers a comprehensive portfolio of products and services, including Rezdiffra.
Treats NASH with moderate to advanced liver fibrosis.
Funding Insights of Madrigal Pharmaceuticals
Madrigal Pharmaceuticals has successfully raised a total of $38.38M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $35 million completed in June 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $38.38M
- Total Rounds 2
- Last Round Series A β $35M
- First Round $3.38M
(Apr 2016)
All 2 funding rounds of Madrigal Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2017 | $35M | Series A | β | β | β |
| Apr 2016 | $3.38M | Series A | β | β | β |
1 investors in total: 1 institutional.
Investors in Madrigal Pharmaceuticals
Madrigal Pharmaceuticals has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Madrigal.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Small molecule drugs are developed for cancer and inflammatory diseases. | 2000 | syntapharma.com | Lexington, United States |
Investor details for Madrigal Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Madrigal Pharmaceuticals
288 people are tracked at Madrigal Pharmaceuticals (142 in leadership, 6 in board & advisors, 140 in team); the tracked headcount is 528.
| Name | Role | Group |
|---|---|---|
Hetal Panchal | Sr. Director, Data Platform And Analytics | Leadership |
Jason Gay | Regional Business Director | Leadership |
Ron Marchessault | Vice President, Head Of Market Access | Leadership |
Kristine Grigoryan | Payroll Director | Leadership |
Zara Gaudioso | Director Human Resources Operations | Leadership |
Parth Patel | Executive Director, AI And Data Science | Leadership |
Nancy B. | Director, Commercial Training & Development | Leadership |
Christopher Milazzo | Sr. Director, Clinical Practice Liaisons | Leadership |
Vanessa MacGregor | Director, Specialty Pharmacy: Market Access | Leadership |
Amir Karimzadeh | Senior Director -nash Medical Sciences | Leadership |
Scott Farris | Sr Director, Health Systems National Accounts | Leadership |
Ken Liu | Senior Director, National Accounts, US Market Access | Leadership |
Brad Giglio | Senior Director National Accounts | Leadership |
Amber Pace | Northeast Regional Sales Director | Leadership |
John O'Donnell | Vice President, Global Health Economics And Outcomes Research | Leadership |
Carlos Blocker | Regional Sales Director | Leadership |
Lauren van Den Heuvel | Senior Director, Market Access Strategy & Operations | Leadership |
Alexandre Felizardo | Executive Director- Market Access | Leadership |
Bob O'Rourke | Vice President, Talent Access | Leadership |
Kelley Anne Bruni | Director, Key Accounts, Health Systems | Leadership |
268 more people are available in the full profile.
Complete people profiles for Madrigal Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Madrigal Pharmaceuticals
Madrigal Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol MDGL in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date07 Nov 2013
- Listed onNASDAQ: MDGL
- Listed entityMadrigal Pharmaceuticals, Inc.
- Exchange sectorHealth technology
- ISINUS5588681057
- Share price$452.12 (-3.22% on the day) · 2026-10-13
- Market capitalisation$10.45B
- EPS (diluted, trailing year)$-12.88
- Volume (last session)315,930
Financials of Madrigal Pharmaceuticals
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $958.4M | -$288.3M | -$298.6M |
| 2024 | $180.1M | -$465.9M | -$496.8M |
| 2023 | -$373.6M | -$380.0M | |
| 2022 | -$295.4M | -$293.1M | |
| 2021 | -$241.8M | -$241.6M |
Detailed financial statements for Madrigal Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Madrigal Pharmaceuticals
5 dated milestones of Madrigal Pharmaceuticals across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Madrigal Pharmaceuticals is founded.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Synta Pharmaceuticals.
- Funding First funding round of $3.4M.
- Funding Latest funding round, Series A, of $35.0M.
Competitors of Madrigal Pharmaceuticals
Madrigal Pharmaceuticals has 3 listed competitors in our database, 3 of them funded. They include NGM Biopharmaceuticals, Nimbus Therapeutics and Altimmune.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ngmbio.com | 2007 | San Francisco, United States | $358.87M | 225 | Biologics are developed for cardio-metabolic and liver diseases. | |
| nimbustx.com | 2009 | Cambridge, United States | $685M | 81 | Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. | |
| altimmune.com | 1997 | Gaithersburg, United States | $58M | 17 | Vaccines for infectious diseases and solid tumors are developed. |
Detailed competitors of Madrigal Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Madrigal Pharmaceuticals
The website of Madrigal Pharmaceuticals (madrigalpharma.com) receives about 54.4K visits a month and ranks #889,142 among all websites worldwide, #1,070 in Biotechnology and Pharmaceuticals.
- Monthly visits54.4K
▲ 50.5% vs previous month
- Unique visitors15.5K
per month
- Global rank#889,142
among all websites
- Category rank#1,070
Health · Biotechnology and Pharmaceuticals
- Bounce rate46%
- Pages per visit1.7
- Average visit1 min 09 sec
- DevicesDesktop 40% Β· Mobile 60%
Websites whose visitors overlap most with Madrigal Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| briacell.com | 100% | 8.1K | #2,386,302 | View details | |
| portola.com | 98% | View details | |||
| phasebio.com | 98% | 2.2K | #11,529,454 | View details | |
| nexgenixpharm.com | 97% | View details | |||
| deciphera.com | 97% | 12.2K | #2,044,202 | View details | |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 27 similar websites and full traffic analytics for Madrigal Pharmaceuticals
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 27 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Metabolic Diseases
3 companies that operate in the same segment as Madrigal Pharmaceuticals (Metabolic Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Madrigal Pharmaceuticals
Complete news archive for Madrigal Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Madrigal Pharmaceuticals
Madrigal Pharmaceuticals was founded in 2011 and raised its 1st funding round 5 years after it was founded.
Madrigal Pharmaceuticals is headquartered in Conshohocken, United States. It is registered at Conshohocken, Pennsylvania, United States.
Madrigal Pharmaceuticals is a funded company, having raised a total of $38.38M across 2 funding rounds to date. The company's 1st funding round was a Series A of $3.38M, raised on Apr 2016.
Madrigal Pharmaceuticals has 528 employees.
Annual revenue of Madrigal Pharmaceuticals is $958.4M as on Dec 31, 2025.
Madrigal Pharmaceuticals was founded in 2011 and is headquartered in Conshohocken, United States. Operations are centered on the development of small molecule therapeutics targeting cardiovascular and metabolic diseases, including non-alcoholic steatohepatitis. The company focuses on advancing drug candidates through clinical stages within the biopharmaceutical sector, with activities spanning research, preclinical testing, and regulatory processes in the United States.
Madrigal Pharmaceuticals's top competitors include Nimbus Therapeutics, NGM Biopharmaceuticals and Altimmune.
Madrigal Pharmaceuticals offers Rezdiffra.
Yes, Madrigal Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol MDGL.
Madrigal Pharmaceuticals has 1 investor. Key investors include Madrigal.
Yes. Madrigal Pharmaceuticals was acquired by Synta Pharmaceuticals in April 2016.

